Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin-Reference-Cited by-同舟云学术

Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin

Published:2021-12 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Lobo Niyati,Hensley Patrick J.,Bree Kelly K.,Nogueras-Gonzalez Graciela M.,Navai Neema,Dinney Colin P.,Sylvester Richard J.,Kamat Ashish M.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference20 articles.

1. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update;Babjuk;Eur Urol,2019

2. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

3. European Association of Urology (EAU) prognostic factor risk groups for non–muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel;Sylvester;Eur Urol,2021

4. Babjuk M, Burger M, Compérat E, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). 2021. https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/.

5. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry;US Food and Drug Administration,2018

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification;Nature Reviews Urology;2024-08-02

2. Handling and pathology reporting guidelines for bladder epithelial neoplasms – recommendations from the Brazilian Society of Pathology / Brazilian Society of Urology / Brazilian Society of Clinical Oncology;Surgical and Experimental Pathology;2024-06-10

3. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial;Nature Medicine;2024-06-06

4. Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette–Guérin Therapy in Non-Muscle-Invasive Bladder Cancer;Cancers;2024-04-26

5. Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI;npj Digital Medicine;2024-04-18